Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (621-630 of 759) with videos related to

Pageof 76
Sort By:
Blood Advances|April 13, 2019
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosisMohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Blood Advances|March 3, 2019
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myelomaNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|December 13, 2018
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcomeAshley R Paquin, Shaji K Kumar, Francis K Buadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
American Journal of Hematology|September 9, 2018
Utility and prognostic value of <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Francis K Buadi, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Leukemia|July 31, 2020
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Pageof 76

Showing results (621-630 of 759) with videos related to

Sort By:
Pageof 76
Blood Advances|April 13, 2019
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosisMohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Blood Advances|March 3, 2019
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myelomaNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|December 13, 2018
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcomeAshley R Paquin, Shaji K Kumar, Francis K Buadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
American Journal of Hematology|September 9, 2018
Utility and prognostic value of <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Francis K Buadi, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Leukemia|July 31, 2020
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Pageof 76